Lyell Immunopharma, Inc. (LYEL) stock analysis

In our weekly check, Lyell Immunopharma, Inc. is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 5 pass, warnings: 4, red flags: 12.

About Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as LYEL.

What our checks show for LYEL

Red flags

• The net margin fell by 1698717 points over 5 years, to -1701067%: the company keeps less of each sale as profit.
• The gross margin fell by 15567 points, to -15467%: costs are rising faster than prices.
• Weak EPS forecast
• Revenue fell 94.4% a year over the last 3 years.
• Weak EPS growth
• The company is losing money.
• Free cash flow is negative: the business spends more cash than it brings in.
• The price swings a lot: 85.1% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 98% from a peak. Would you have held through that?
• The share count grew by 36.2% in 2 years: each shareholder owns a smaller slice.
• Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
• Pay in shares equals 0% of free cash flow: it dilutes shareholders.

Warning signs

• Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
• A small company (market value $364 million): usually riskier and followed by fewer analysts.
• The stock is still below its previous peak.
• Thinly traded (about 164 thousand shares a day): buying and selling can move the price.

Strengths

• Debt is low: 0.18x equity.
• Analysts expect revenue to grow about 3400% a year over the next years.
• Analysts expect the net margin to improve by 1700826 points from today's -1701067%.
• Beta -0.07: the stock usually moves less than the market.

Similar companies

AVTX · RZLT · IRD · FENC · OBIO

Questions

What grade does Lyell Immunopharma, Inc. (LYEL) have?

In our weekly check, Lyell Immunopharma, Inc. is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 5 pass, warnings: 4, red flags: 12. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of LYEL stock?

This week's biggest flags for Lyell Immunopharma, Inc.: Margins falling, Gross margin falling, Weak EPS forecast. In total 16 of 21 checks show a warning or a red flag.

What does Lyell Immunopharma, Inc. do?

Lyell Immunopharma, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as LYEL.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-07

Open the full analysis